Tags

Type your tag names separated by a space and hit enter

Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
Curr Med Res Opin. 2005 Sep; 21(9):1453-60.CM

Abstract

OBJECTIVE

Poor compliance and persistence with bisphosphonates is a concern in postmenopausal osteoporosis due to its negative impact on fracture risk and healthcare costs as well as quality of life. Reducing oral bisphosphonate dosing frequency is one measure available to increase therapy convenience and practicality, with the hope of improving compliance and persistence. This study compared compliance and persistence with weekly and daily bisphosphonate regimens for postmenopausal osteoporosis.

METHODS

Administrative claims data (1997-2002) from 30 health plans were used to identify postmenopausal women (> 45 years) with osteoporosis, who had been newly prescribed a once-weekly (QW alendronate 35 mg or 70 mg) or once-daily (QD alendronate 5 mg or 10 mg or risedronate 5 mg) bisphosphonate. QW and QD cohorts were followed for 12 months from initial prescription. Medication possession ratios (MPRs) measured refill compliance during follow-up. Persistence was calculated as the number of days from the initial prescription to a lapse of > 30 days after completion of the previous refill.

RESULTS

Data were available for 2741 women (QW, N = 731, QD, N = 2010). QW users had significantly higher medication compliance than QD users (69.2% vs. 57.6% MPR, p < or = 0.0001). QW users persisted with therapy significantly longer than QD users (p < 0.0001) and had higher rates of retention on treatment at 12 months than QD users (44.2% QW; 31.7% QD). Dosing frequency was the strongest predictor of time to discontinuation (p < 0.0001).

CONCLUSIONS

Postmenopausal women prescribed a weekly bisphosphonate had significantly better compliance and persistence than those taking more frequent, daily bisphosphonate doses. However, compliance and persistence rates for both regimens were suboptimal, suggesting that less frequent dosing intervals may provide an opportunity to further improve the consistent use of bisphosphonate therapy.

Authors+Show Affiliations

Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. joyce.cramer@yale.eduNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16197664

Citation

Cramer, Joyce A., et al. "Compliance and Persistence With Bisphosphonate Dosing Regimens Among Women With Postmenopausal Osteoporosis." Current Medical Research and Opinion, vol. 21, no. 9, 2005, pp. 1453-60.
Cramer JA, Amonkar MM, Hebborn A, et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005;21(9):1453-60.
Cramer, J. A., Amonkar, M. M., Hebborn, A., & Altman, R. (2005). Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Current Medical Research and Opinion, 21(9), 1453-60.
Cramer JA, et al. Compliance and Persistence With Bisphosphonate Dosing Regimens Among Women With Postmenopausal Osteoporosis. Curr Med Res Opin. 2005;21(9):1453-60. PubMed PMID: 16197664.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. AU - Cramer,Joyce A, AU - Amonkar,Mayur M, AU - Hebborn,Ansgar, AU - Altman,Roy, PY - 2005/10/4/pubmed PY - 2005/10/29/medline PY - 2005/10/4/entrez SP - 1453 EP - 60 JF - Current medical research and opinion JO - Curr Med Res Opin VL - 21 IS - 9 N2 - OBJECTIVE: Poor compliance and persistence with bisphosphonates is a concern in postmenopausal osteoporosis due to its negative impact on fracture risk and healthcare costs as well as quality of life. Reducing oral bisphosphonate dosing frequency is one measure available to increase therapy convenience and practicality, with the hope of improving compliance and persistence. This study compared compliance and persistence with weekly and daily bisphosphonate regimens for postmenopausal osteoporosis. METHODS: Administrative claims data (1997-2002) from 30 health plans were used to identify postmenopausal women (> 45 years) with osteoporosis, who had been newly prescribed a once-weekly (QW alendronate 35 mg or 70 mg) or once-daily (QD alendronate 5 mg or 10 mg or risedronate 5 mg) bisphosphonate. QW and QD cohorts were followed for 12 months from initial prescription. Medication possession ratios (MPRs) measured refill compliance during follow-up. Persistence was calculated as the number of days from the initial prescription to a lapse of > 30 days after completion of the previous refill. RESULTS: Data were available for 2741 women (QW, N = 731, QD, N = 2010). QW users had significantly higher medication compliance than QD users (69.2% vs. 57.6% MPR, p < or = 0.0001). QW users persisted with therapy significantly longer than QD users (p < 0.0001) and had higher rates of retention on treatment at 12 months than QD users (44.2% QW; 31.7% QD). Dosing frequency was the strongest predictor of time to discontinuation (p < 0.0001). CONCLUSIONS: Postmenopausal women prescribed a weekly bisphosphonate had significantly better compliance and persistence than those taking more frequent, daily bisphosphonate doses. However, compliance and persistence rates for both regimens were suboptimal, suggesting that less frequent dosing intervals may provide an opportunity to further improve the consistent use of bisphosphonate therapy. SN - 0300-7995 UR - https://www.unboundmedicine.com/medline/citation/16197664/Compliance_and_persistence_with_bisphosphonate_dosing_regimens_among_women_with_postmenopausal_osteoporosis_ L2 - https://www.tandfonline.com/doi/full/10.1185/030079905X61875 DB - PRIME DP - Unbound Medicine ER -